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A B S T R A C T
Transcription factors from the Ikaros family are involved in lymphocyte differentiation and have a critical role at spe-
cific check points of the haemopoietic pathway. However, how developmentally regulated changes are reflected in gene ex-
pression programs of lymphocyte differentiation is not well understood. It has been suggested that disregulation of tran-
scription factors from the Ikaros family is associated with the development of different human leukemias. In this work
we analyzed the state of Ikaros family members in different leukemic cells with the aim to explore the transcriptional con-
trol of human hematopoietic lineages and shed some new light on our understanding of transcription factor significance
in human leukemias. By means of RT-PCR and specific primers we investigated the expression of Ikaros, Aiolos and
Helios transcription factors and their splicing variants in seven leukemia cell lines derived from different types of leuke-
mia (ALL, CML, AML) and lymphoma (histiocytic lymphoma, Burkitt lymphoma and anaplastic large cell lymphoma).
In all of the cell lines examined Ikaros was present in dominant Ik1 to Ik4 isoforms and small Ik6 isoform was absent.
Aiolos was expressed in the majority of the cell lines, of both, B and T origin, in the form of the full length Aio1. Helios
was also present only in two long isoforms Hel1 and Hel2, and was absent in one third of the lines. Similar distribution
of positive and negative expression of Aiolos and Helios found in various types of leukemias could implicate common
pathways of their regulation.
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Introduction
Hematopoietic cells develop from their stem cells and
gain their function just as mature peripheral blood cells.
Their differentiation is regulated by a number of genes
that are either silenced or activated in a sequenced order.
This process is extremely complex and constantly sub-
jected to various external influences. Developmental
pathway of hematopoietic cells include hierarchical acti-
vation/silencing of specific transcription factors, among
which Ikaros family are now recognized as important
regulators of haemotopoietic and particularly lymphoid
differentiation1,2. In this process three members of the
Ikaros family are involved: Ikaros, Aiolos and Helios.
They all have a very similar structure: an amino termi-
nal domain mediating sequence-specific DNA binding
and a carboxy terminal domain involved in the formation
of homo and heterodimers3, structure additionally being
complicated by isoform formation due to mRNA alterna-
tive splicing. Long isoforms usually have at least three of
four Zn finger binding domains and can functionally bind
DNA. On the other hand some of the splicing occurs in
the DNA binding domain resulting in short isoforms
(Ik4–Ik8, Hel5–Hel8, Aio4) which lack two or more Zn
finger domains. They cannot bind DNA and could act in a
dominant negative manner, forming dimers with long
isoforms (Figure 1).
As to regulation of lymphoid development, Ikaros
transcription factors appears to be involved in the differ-
entiation of both T and B lymphocytes, NK cells, mono-
cytes/macrophages, dendritic cells and neutrophyles. Its
abrogation in knock-out mice and in some rare types of
leukemia leads to aberrant development of T cell lines.
Analysis of Ikaros member downregulation in different
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types of leukemia suggest that it may also play an impor-
tant role in nonlymphoid lineages4.
Aiolos transcription factor seems to be involved pri-
marily in B cell differentiation5,6. Interplay among Aiolos
and other specific transcription factors was found to de-
termine subtle differentiation stages in B cell develop-
ment7.
Helios, the third member of Ikaros family, was found
to be important in T cell development8,9. Thus, constant
expression of the full length Helios resulted in an inhibi-
tion of T cell development, and the non-DNA binding
forms were able to induce lymphoma10. The role of Helios
in B cell development was also demonstrated11.
Although still widely unknown, the intricate inter-
play among these three Ikaros transcription factors, as
well as with other transcriptional regulators is started to
be revealed. As various types of leukemia are suggested
to mirror differentiation stages of hematopoietic cells
freezed in their development, in this work we analyzed
the state of Ikaros family members in different types of
human leukemic cell lines. We compared the expression
pattern of their isoforms/splicing variants and discussed
their expression in relation to the cell phenotype.
Methods
Cell lines
Human leukemia/lymphoma cell lines Jurkat (T-lin-
eage ALL), MOLT-4 (T-lineage ALL), NALM-1 (CML in
blast crisis), HL-60 (AML), U-937 (histiocytic lympho-
ma), RAJI (Burkitt’s lymphoma) and SU-DHL-1 (ana-
plastic large cell lymphoma) were maintained in RPMI
1640, supplemented with 10% heat-inactivated fetal bo-
vine serum (Invitrogen Co.).
RNA extraction, preparation of cDNA
Total RNA was extracted using Trizol (Invitrogen
Co.) and the quality of RNA was monitored through
agarose gel electrophoresis. 2 ml of isolated RNA was
used for cDNA synthesis using the standard protocol for
Superscript II Rnase H Reverse Transcriptase (Invitro-
gen Co.).
Polymerase chain reaction
A volume of 25 ml for PCR was performed using 2.5 ml
of cDNA, 2.5 ml of 10´PCR buffer, 1.8 ml of 25 mMMgCl2,
0.5 ml of 10 mM dNTP, 1 ml of each 5 mM primer, 0.2 ml of
5U Ampli Taq gold polymerase (Applied Biosystems) and
15.5 ml of H2O.
The sequences of the primers used are as follows:
Ikaros sense primer Hex2F, 5’ cccctgtaagcgatactccagatg
3’, antisense primer Hex7R, 5’ gatggcttggtccatcacgtggga
3’; Aiolos sense primer 5’ cactcaggagcagtctgtgc 3’, an-
tisense primer 5’ agaaggcacgctcttctctg 3’; Helios sense
primer Hev S, 5’ atggaaacagaggctattgatggc 3’, antisense
primer Hev 2, 5’ agcttttcccccacaaactt 3’; HPRT sense
primer (HPRT1), 5’ ccaaagatggtcaaggtcgc 3’, and anti-
sense primer HPRT 2, 5’ ctgctgacaaagattcactgg 3’.
PCR cycling conditions were: 94 °C for 5 min (dena-
turation); 94 °C for 30 s; 59 °C (Ikaros), 58 °C (Aiolos and
Helios) and 52 °C (HPRT) for 30 s; 72 °C for 1 min for 40
cycles; 72 °C for 7 min.
Results
We compared the pattern of expression of Ikaros,
Aiolos and Helios between cell lines originating from dif-
ferent types of human hematopoietic malignancies. In
the analysis 7 different leukemic cell lines were included:
human T cell leukemia lines Jurkat and MOLT-4 (ALL);
human B cell leukemia lines NALM-1and SUDHL-1;
lines of myeloid origin HL-60 (AML) and U-937; and
RAJI cells originating from a human Burkitt’s lym-
phoma. Figure 2 shows that all cell lines analyzed ex-
pressed Ikaros mRNA as a full length Ik1. Most of leu-
keia cells also express spliced variants Ik2, Ik3 and
weakly Ik4. Dominant negative Ik6 was not detected in
any of the cell lines. Figure 2 also shows that Aiolos, in
the largest full length form of Aio1 was strongly ex-
pressed in Jurkat, MOLT-4 and Nalm-1 cells i.e. in cells
of B and T origin. In contrary, myeloid cells HL-60 (AML)
and U-937 had a very weak expression of the longest
isoform Aio1. The Burkitt’s lymphoma derived RAJI
cells and B cell leukemia SUDHL-1 did not express either
full length Aiolos or any form of Aiolos variants. Interest-
ingly, Helios transcription factor was expressed in Jur-
kat, MOLT-4 and NALM-1, but also in cell strains of
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Fig. 1. Shematic representation of various Ikaros isoforms17,26.
myeloid origin, HL60 and U-937. Figure 2 also shows the
expression of dominant Helios isofroms Hel 1 and Hel 2.
Likewise Aiolos, Helios could not be detected in Raji and
SUDHL-1 cells.
Discussion and Conclusion
We analyzed the expression of Ikaros family mem-
bers, Ikaros Aiolos and Helios in a panel of different
types of human leukemic cells, in order to explore if the
expression pattern of their splicing variants is related to
each other and/or to specific type of leukemic cells.
Ikaros plays an important role in controlling hemato-
poietic differentiation and has been implicated in lym-
phoid development and proliferation12,13, as well as in
malignant transformation14–17. It has been found that
high levels of alternatively spliced Ik6 isoform, lacking
DNA binding domain impair the function of Ikaros pro-
teins in a dominant negative manner18.
In our set of leukemia cell lines, all of the samples
were positive for Ikaros expression. Predominant were
high molecular weight isoforms, unspliced Ik1, as well as
Ik2 and Ik3. Isoform Ik4 was found, but in a low concen-
tration, while dominant negative Ik6 was not detected.
The same expression pattern of Ikaros splicing variants
could be found in normal blood samples. Previously, anal-
ysis of Ikaros transcription factors was performed in sev-
eral clinical studies on leukemia patients, showing aber-
rant expression of its isoforms, specifically Ik6, Ik4, Ik7
and Ik8, in different types of leukemia16,17,19. Thus, over-
expression of short dominant negative Ik6 was found to
correlate with the development of the childhood ALL17 in
both, B and T ALL subtypes20,21. It has been suggested
that aberrant Ikaros splicing could be the consequence of
Bcr-Abl translocation, present in infant lymphocytic leu-
kemia15. Ik6 variant was also found in adult types of leu-
kemia, CML (chronic myelogenous leukemia), ALL and
AML, but in significantly lower number of cases22,23.
As our samples of leukemic cell lines originated from
adult types of leukemia, approximately normal pattern of
Ikaros expression is in line with previous findings24. We
have shown that the expression of Ikaros splicing vari-
ants in leukemic cell lines was similar to that obtained
from human leukemias, with dominant Ik1 to Ik4 iso-
forms and absence of Ik6.
Another transcription factor from the Ikaros family,
Aiolos, is considered to have an antiproliferative role in B
lymphocyte function. However, its role in human lym-
phoid disorders is still unclear. Different Aiolos splice
variants were found in both, normal and neoplastic B lin-
eage cells25. Our samples of cell lines, originating from
different types of leukemia, were predominantly positive
for Aiolos, and expressed the full length form Aio1.
Aiolos was expressed in several cell lines of both, B and T
origin: in Jurkat, MOLT-4 and NALM-1. In cells of mye-
loid origin Aio1 was weakly expressed. No Aiolos in RAJI
and SUDHL-1 cells was detected, reflecting some differ-
ences in its expression pattern depending on the type of
leukemia as we have shown before in leukemic patients25.
Helios, as the third member of Ikaros family, is the
least explored. In mice, Helios downregulation was found
to interfere with T cell maturation8,9. In normal blood
Helios is expressed in two isoforms, Hel1 and Hel2 (data
not shown). Only in sporadic tumor cell lines and one
leukemia patient small spliced and deleted forms of He-
lios, Hel5, Hel6, Hel7 and Hel8 were found22. In the cell
lines tested we could detect two splicing variants Hel1
and Hel2, but apparently these cells do not have other
deleted or spliced forms of Helios. Considering all of the
samples analyzed, originating from different types of leu-
kemic cell lines, it could be concluded that Ikaros was
ubiquitously expressed, in normal splice variants. Aiolos,
in full-length isoform, was present in all samples except
for RAJI and SUDHL-1. Helios, normally expressed in
peripheral blood leukocytes, was absent in one third of
hematopoietic tumor cell lines. We also observed that
several cell lines without Aiolos neither expressed He-
lios: two B cell strains (RAJI and SUDHL-1). Similar dis-
tribution of positive and negative expression of Aiolos
and Helios found in various types of leukemias could im-
plicate common pathways of regulation. We conclude
that the cell lines used are a suitable model for Ikaros
transcription factor analysis and for further studies of
mechanisms involved in differentiation and leukemia de-
velopment.
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Fig. 2. RT-PCR analysis of Ikaros, Aiolos and Helios gene ex-
pression in freshly isolated human derived cell lines. Amplifica-
tion products with primers as described in Methods as full len-
gth and splicing variants. HPRT is a house keeping control gene.
Lane 1 – M (marker, base pairs), Lane 2 – T lymphocytes (Jur-
kat), Lane3 (T lymphocytes MOLT-4), Lane 4 – mature B lympho-
cytes (NALM-1), Lane 5 – acute myeloid leukaemia (HL- 60) La-
ne 6 – immature monocytes U 937, Lane 7 – Burkitt’s lymphoma
derived cells (RAJI), Lane 7- B lymphocytes (SUDHL-1).
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ANALIZA TRANSKRIPCIJSKIH FAKTORA IZ OBITELJI IKAROS U HEMATOPOETSKIM
STANICAMA LJUDI
S A @ E T A K
Transkripcijski faktori iz obitelji Ikaros imaju kriti~nu ulogu u specifi~nim kontrolnim to~kama hematopoetskog
puta. S obzirom na njihovu va`nost u razvoju hematopoetskih stanica upravo se transkripcijski faktori iz obitelji Ikaros
dovode u vezu s razvojem leukemija. U ovom radu analizirali smo ekspresiju ~lanova obitelji Ikaros – Ikaros, Aiolos i
Helios, u razli~itim stani~nim lozama koje potje~u iz leukemija ljudi s ciljem upoznavanja njihove uloge u razvoju leuke-
mija. Metodom reverzne transkripcije (RT-PCR) i specifi~nih po~etnica istra`ili smo ekspresiju glasni~ke RNA za Ika-
ros, Aiolos i Helios kao i oblika nastalih izrezivanjem RNA (»splicing variants«) u sedam stani~nih loza nastalih iz
razli~itih tipova leukemija ljudi (ALL, CML, AML) i limfoma (histiocitni limfom, Burkittov limfom i anaplasti~ni lim-
fom velikih stanica). U svim stani~nim lozama na{li smo da se Ikaros ispoljava u svojem najduljem obliku Ik1 i kra}im
izrezanim izoformama Ik2, Ik3 i Ik4 dok izostaje najkra}i Ik6 oblik. Aiolos je eksprimiran u ve}ini stani~nih loza, kako
limfocita B tako i limfocita T, u svojem punom obliku Aio1. Prisutnost transkripcijskog faktora Helios je tako|er pred-
stavljena s dvije najdulje izoforme Hel1 i Hel2 koje, me|utim, nedostaju u jednoj tre}ini stani~nih loza. Sli~na ras-
podjela ekspresije Aiolos i Helios na|ena u razli~itim tipovima leukemija implicira zajedni~ki put njihove regulacije.
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